Who We Are

CellVec is a gene therapy Contract Development and Manufacturing Organisation (CDMO).


We specialise in research, translational development and GMP manufacturing of gene transfer vectors.

Guided by the extensive experience of our founders, Dr Lucas Chan and with the use of our lentivirus-based CellVec Vector Platform, we set ourselves apart through the ability to overcome current technological bottlenecks in the upscale production of viral vectors and develop novel gene transfer technologies for advanced therapies in order to facilitate the advancement of our client’s products from bench-to-bedside for clinical applications.

CellVec is a subsidiary of TalkMed Group.

The established premier provider of medical oncology and palliative care in Asia.


CellVec was first conceived as the cell and gene therapy division of Stem Med, a joint venture between the TalkMed Group and Stemcord Pte Ltd. Stem Med’s focus lies in the development of an adult stem cell bank for advanced therapeutic use. In August 2018, CellVec was spun-off from Stem Med to further our dedication to bringing gene therapy to patients-in-need.


March 2017
CellVec Advanced Therapy Division was established within Stem Med Pte Ltd, Singapore
May 2017
CellVec’s Research and Process Development laboratories were established
August 2017
Feasibility study on CellVec’s GMP facility was completed
September 2017
Convened consultations with Health Sciences Authority (HSA) on the facility design
December 2017 – June 2018
Design and construction of CellVec’s GMP facility commenced
August 2018
CellVec was established as a Pte Ltd
End 2018
Construction of CellVec’s GMP facility completed
End 2018
CellVec’s lentivirus-based platform established (CellVec Vector Platform)
Q1 2019
CellVec’s GMP facility Start Up with Performance Qualification
Q2 2019
CellVec’s GMP manufacturing goes online